gel-e-logo

gel-e is developing a line of advanced hemostatic and wound treatment products that address unmet needs from the operating room to the backyard.  Following previous clearances for topical and external use of its platform technology (see http://www.gel-e.co/news.html), the Company is now expanding its label to include use for internal and surgical applications.  The first product, now on an accelerated path as a Breakthrough Device, is an expanding injectable hemostat, Life Foam™.   Life Foam can rapidly provide temporary control of bleeding from non-compressible abdominal wounds that are not amenable to tourniquet application in trauma and battlefield conditions.  As the tradename suggests, this product is designed to save the lives of those injured in battle, or that are the victims of traumatic accidents or even terrorist attacks.  

biotalk-doerfler-maxcyte-article-image.jpg

MaxCyte Founder, President and CEO Doug Doerfler joins BioTalk to discuss his history and the growth of the company. He also shares advice for entrepreneurs

Mr. Doerfler has more than 35 years of experience in the discovery, development, commercialization and international financing of biotechnology products and companies. He was a founder of MaxCyte in July 1998. Previously, Mr. Doerfler was President, CEO and a Director of Immunicon Corporation, a cell-based therapy and diagnostics company. He also held various executive positions with Life Technologies, Inc.(now Thermo Fisher Scientific). Mr. Doerfler plays an active role as a life sciences industry advocate, serving as Chair Emeritus of the MTC and on the executive committee of BIO.

Listen now on iTunes (https://apple.co/318CzZv), Google (http://bit.ly/30WiQfg), and TuneIn (http://bit.ly/2LPtYab).

redwine-glass-pixa

A nice, relaxing glass of Bordeaux or Cabernet might easily seem like the perfect treatment for an anxious or slightly depressed state. Though, the alcohol might lead one down a slippery path rather quickly. Instead, investigators at the University of Buffalo (UB) and Xuzhou Medical University in China have decided to focus their attention on the widely studied plant compound—found in considerably higher levels in red wine than most other plants—called resveratrol. This phenolic compound has been studied for several decades, in connection with reduced incidence of cardiovascular disease and for the treatment of cancer, with mixed results. Yet now, researchers found new evidence of resveratrol displaying anti-stress effects by blocking the expression of an enzyme related to the control of stress in the brain.

bhi-george-mason-gmu-logo

A patent granted to George Mason University Research Foundation Inc., which describes a novel treatment method for pre-invasive breast cancer, has been exclusively licensed to Targeted Pharmaceuticals LLC, a clinical-stage biopharmaceutical company focused on utilizing cannabinoids for the treatment of  oncology and central nervous system disorders.

brainscope-logo

BrainScope announced today that it has successfully completed a nearly five year, $9.9 million U.S. Department of Defense research contract supporting the development and validation of an objective marker of the presence and severity of concussion. In a large blinded validation study, the system demonstrated its ability to help clinicians assess concussion at the time of injury, reflect severity of injury, and aid in their assessment of readiness to return to activity. BrainScope extended the work performed under this Department of Defense contract to include adolescents funded through private investment from BrainScope and a second award from the NFL-GE Head Health Challenge I.

childrens-national-health-system-logo

The Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National Health System announces its 7th Annual Pediatric Device Innovation Symposium is slated for Sunday, Sept. 22 in Boston, Mass., featuring a $150K medical device competition focused on innovations for neonatal and NICU care. Following the theme "Pediatric Device Clinical Trials: Forging a Better Path," this year's symposium explores the pediatric device clinical trial process, including progress insights, current challenges and potential solutions.

frederick-county-ec-dev-logo

Frederick, Maryland continues to be a hotbed for biotech and a destination of choice for many new startups. The last few years have seen one-time startups like RoosterBio, Inc., BioFactura, Inc. and Akonni Biosystems thrive and grow within the Frederick life science support ecosystem. 

bhi-george-mason-gmu-logo

A patent granted to George Mason University Research Foundation Inc., which describes a novel treatment method for pre-invasive breast cancer, has been exclusively licensed to Targeted Pharmaceuticals LLC, a clinical-stage biopharmaceutical company focused on utilizing cannabinoids for the treatment of oncology and central nervous system disorders.

leadership-team-pixa

If you attended any of the events, conferences and panel discussions in the BioHealth Capital Region this year you probably would have picked up on a consistent theme. Whether it was at the ISPE Chesapeake Bay Area Chapter’s MAST Showcase, the BioHealth Capital Region Forum held at AstraZeneca in April or the more recent NCI Tech Transfer Showcase, talent and capital were hot button topics discussed intensely during the sessions, over lunch and while networking at each event. 

emmes-logo

Emmes today announced that it has received a Workplace Excellence Seal of Approval from Alliance for Workplace Excellence (AWE). This is the fifth consecutive year the company has received the AWE Workplace Excellence award.

MaxCyte-logo

MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announced today that it has appointed Dr. Dhana Chinnasamy, a 20+-year expert in the research and translation of gene and immunotherapies, as its Vice President, Non-Clinical and Translational Studies. In her new role, Dr. Chinnasamy will oversee all non-clinical and translational activities for MaxCyte's CARMA platform working closely with the clinical, regulatory, manufacturing, and business development teams in support of MaxCyte's clinical-stage therapeutic development.

biopharma-laboratory-lab-pixa

The Biotechnology Innovation Organization (BIO) recently released the report Transforming Ideas into Advances: Best Practices in State and Regional Bioscience Economic Development Initiatives. This biennial report provides a good summary of state initiatives serving the industry plus a discussion of new developments by state.

washington-view-3-pixa

I recently visited Egypt as part of a team led by the Departments of State and Agriculture, supported by the good folks at the AUTM Foundation. Egypt, like many countries, is looking at our model for integrating research universities into their economy. I was asked to speak about the Bayh-Dole Act and thought it was important to emphasize that there were many factors required beyond enacting a law to reverse an entrenched national policy.

alexandria joel marcus logo

Alexandria Real Estate Equities, Inc. (NYSE: ARE), an urban office REIT and the first and longest-tenured owner, operator and developer uniquely focused on collaborative life science, technology and agtech campuses in AAA innovation cluster locations, today announced that it has been selected by NAIOP, the Commercial Real Estate Development Association, as the 2019 Developer of the Year. The award, which is the association's highest honor, will be presented to Alexandria at a ceremony on Wednesday, October 16, 2019, at NAIOP's CRE.Converge conference in Los Angeles.

dna-genetics-pixa

If companion diagnostics (CDx) were people, they would be old enough to drink. The first CDx won FDA approval in 1998, when Dako Denmark (since acquired by Agilent Technologies) received authorization to market HercepTest. The immunohistochemistry (IHC) assay was designed to detect human epidermal growth factor receptor 2 (HER2) protein overexpression in breast tumors of patients who may benefit from Herceptin (trastuzumab), a targeted therapeutic for certain types of breast cancer marketed by Genentech (now a member of the Roche Group).

marcus-joel-alexandria-real-estate-image

Earlier today, NAIOP announced it had chosen Alexandria Real Estate Equities its 2019 Developer of the Year, the organization's highest honor. "Founded on the premise that life science companies are most successful when positioned in close proximity to world-renowned academic and medical institutions, cutting-edge scientific and managerial talent and strategic investment capital," said NAIOP, "Alexandria has utilized Harvard Business School Professor Michael E. Porter's cluster theory as the foundation of its differentiated and multifaceted business model."

women-in-bio-logo

When:Tuesday, July 30, 2019

Join Women In Bio-Capital Region to discuss one of the most important elements of entrepreneurship - how to determine whether to bring start-up team members in-house (and creatively convince them to work for your startup), or utilize vendors and contractors (and vet and manage them). We are excited to present an excellent panel of strong female professionals with diverse expertise in launching and facilitating successful businesses in the biotech space. Our panel will feature: Emily English, Ph.D. and CEO of Gemstone Biotherapeutics; Anne Balduzzi, Director of Advisory Services at TEDCO; and Maria Granovsky, Ph.D., J.D., and founder of Swimming Otter Communications. Dr. Ethel Rubin, Entrepreneur-in-Residence at BioHealth Innovation, Inc. will be our moderator for the evening, helping to highlight the panelists’ inspirational stories and cautionary tales of how to successfully start your own business (typically with little funding). Come prepared to listen, learn, ask questions, and have the opportunity to meet the leading ladies of our entrepreneurship-focused WIB evening. We can’t wait to see you there!

galien-foundation-logo

The Galien Foundation today announced the 2019 Annual Prix Galien USA Award nominees. Counted among the global health innovation industry's most prized honors, the Prix Galien Award recognizes outstanding biomedical and medical technology product achievement that improves the human condition.

umd-ibbr-0608-logo

Researchers at the Institute for Bioscience and Biotechnology Research (IBBR) recently received $1M from the Defense Threat Reduction Agency (DTRA, part of the US Department of Defense) to advance their work developing wearable sensors that measure biochemical information to diagnose disease. IBBR Fellow Dr. Gregory Payne (Research Professor, IBBR) is principal investigator on the award.

Ethel-Rubin.jpg

What is the NIH and how is NIH related to venture capital? Isn’t NIH a government research organization? NIH is widely recognized as the world’s premier biomedical research agency. Few realize that NIH, through its Small Business Innovation Research and Small Business Technology Transfer programs, is also the world’s largest early stage life sciences investor. We back over 1000 companies each year with over $1B! Companies that are awarded these much-coveted, non-dilutive awards for product development cannot do it alone. We need private, institutional and venture fund partners to help these companies bring products to market. That is where the investment world comes in.